---
id: 111
title: Enterobacterales and Resistance Mechanisms
category: organisms
subcategory: gram_negative_rods
tags: [Enterobacterales, ESBL, CRE, KPC, E-coli, Klebsiella, carbapenemase]
difficulty: medium
---

## Question

What are the key resistance mechanisms in Enterobacterales? Use the **"ESBL → Carbapenemase (KPC, NDM, OXA-48)"** escalation framework.

## Answer

### **Resistance Mechanisms:**

| Resistance | Mechanism | Phenotype | Treatment |
|------------|-----------|-----------|-----------|
| **ESBL** | Extended-spectrum β-lactamase | Resistant to **cephalosporins** (including 3rd/4th gen), **penicillins**; Susceptible to **carbapenems** | **Meropenem 1g IV q8h** OR **ertapenem 1g IV daily** (non-severe) |
| **AmpC** | Chromosomal β-lactamase (inducible) | Resistant to **cephalosporins** (including cefepime if high-level); Susceptible to **carbapenems** | **Meropenem** OR **cefepime 2g IV q8h** (if susceptible) |
| **CRE (Carbapenem-Resistant)** | **Carbapenemase** (KPC, NDM, OXA-48) or **porin mutations** | Resistant to **carbapenems**, often **pan-resistant** | **Combination therapy:** Ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, colistin, tigecycline, aminoglycosides |

### **ESBL (Extended-Spectrum β-Lactamase):**

**Organisms:**
- ***E. coli***, ***Klebsiella*** spp. (most common)
- *Proteus*, *Enterobacter*, *Salmonella*

**Treatment:**
- **Carbapenems** (meropenem, ertapenem) - **First-line**
- **Carbapenem-sparing options (if susceptible):**
  - **Piperacillin-tazobactam** (UTI, low inoculum infections) - controversial
  - **Cefepime** (if MIC ≤2) - limited data
  - **Fluoroquinolones, TMP-SMX** (if susceptible) - for UTI

**Risk Factors:** Recent antibiotic use (especially cephalosporins, fluoroquinolones), healthcare exposure, travel to endemic areas (India, Middle East)

### **CRE (Carbapenem-Resistant Enterobacterales):**

**Carbapenemase Types:**

| Enzyme | Class | Characteristics | Treatment |
|--------|-------|-----------------|-----------|
| **KPC** | Class A (serine) | Most common in US, *Klebsiella* | **Ceftazidime-avibactam**, **meropenem-vaborbactam** |
| **NDM** | Class B (metallo-β-lactamase, MBL) | Asia, Middle East, resistant to **all β-lactams except aztreonam** | **Aztreonam + ceftazidime-avibactam**, colistin, tigecycline |
| **OXA-48** | Class D | Europe, Middle East, low-level carbapenem resistance | Combination therapy (case-by-case) |

**Treatment Principles:**
- **Combination therapy preferred** (polymyxins, tigecycline, aminoglycosides, high-dose carbapenems if MIC ≤8)
- **New agents:**
  - **Ceftazidime-avibactam** 2.5g IV q8h (KPC, OXA-48, ESBL)
  - **Meropenem-vaborbactam** 4g IV q8h (KPC)
  - **Imipenem-relebactam** 500mg IV q6h (KPC)
  - **Cefiderocol** 2g IV q8h (MBL, including NDM)

## Key Points

### **ESBL Detection:**
- **Phenotype:** Cephalosporin-resistant (including ceftriaxone, ceftazidime), but carbapenem-susceptible
- **Mechanism:** Hydrolyzes extended-spectrum cephalosporins (not carbapenems)
- **Inducible:** Not inducible (unlike AmpC)

### **Carbapenemase Detection:**
- **CIM (Carbapenemase Inactivation Method)** or **mCIM (modified CIM)**
- **Molecular testing:** PCR for *bla*KPC, *bla*NDM, *bla*OXA-48

### **AmpC vs ESBL:**
- **AmpC:** Chromosomal (inducible), not inhibited by β-lactamase inhibitors
- **ESBL:** Plasmid-mediated, inhibited by β-lactamase inhibitors (clavulanate, tazobactam)

### **Clinical Pearls:**
- **ESBL:** Carbapenems first-line (ertapenem for non-severe, meropenem for severe)
- **CRE:** Combination therapy, new β-lactam/β-lactamase inhibitors (ceftazidime-avibactam, meropenem-vaborbactam)
- **KPC:** Ceftazidime-avibactam or meropenem-vaborbactam
- **NDM (MBL):** Aztreonam + ceftazidime-avibactam OR cefiderocol
- **Infection control critical:** Contact precautions, single-patient rooms

## Sources

- [CDC: CRE Guidelines 2024]
- [IDSA: CRE Treatment Guidelines 2023]

## Media

N/A
